Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Venous Thromboembolism and the Risk of Death and Graft Loss in Kidney Transplant Recipients.
N. Lam,¹ A. Garg,² G. Knoll,³ J. Kim,⁴ K. Lentine,⁵ E. McArthur,⁶ K. Naylor,⁶ S. Bota,⁶ M. Sood.³
¹University of Alberta, Edmonton, Canada; ²Western University, London, Canada; ³University of Ottawa, Ottawa, Canada; ⁴University of Toronto, Toronto, Canada; ⁵Saint Louis University School of Medicine, St. Louis; ⁶Institute for Clinical Evaluative Sciences, London, Canada
Background: The incidence of venous thromboembolism (VTE) in kidney transplant recipients varies widely in the literature. The implications of VTE for morbidity and mortality in…
2017 American Transplant Congress
Induction of Delayed Renal Allograft Tolerance Using Only Clinically Available Reagents in Non-Human Primates.
K. Hotta, T. Oura, A. Dehnadi, S. Boskovic, M. Matsunami, I. Rosales, N. Smith, R. Colvin, A. Cosimi, T. Kawai.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
Background: We have previously reported successful induction of renal allograft tolerance following a period of conventional immunosuppression (Delayed tolerance) using nonmyeloablative conditioning that included anti-CD154…
2017 American Transplant Congress
Increased Long-Term Mortality 20 years After Living Kidney Donation.
G. Mjoen,¹ S. Hallan,² H. Holdaas.¹
¹Dpt of Transplantation, Rikshospitalet, Oslo, Norway; ²Dpt of Nephrology, St. Olavs Hospital, Trondheim, Norway
Living kidney donors are healthy at the time of donation. Consequently, a long observation period is necessary to detect possible detrimental effects of donation. Most…
2017 American Transplant Congress
Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.
F. Eskandary,¹ B. Jilma,² J. Muehlbacher,³ M. Wahrmann,¹ H. Regele,⁴ N. Kozakowski,⁴ S. Panicker,⁵ J. Reeve,⁶ P. Halloran,⁶ J. Gilbert,⁵ G. Bohmig.¹
¹Department of Medicine III, Medical University Vienna, Vienna, Austria; ²Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria; ³Department of Surgery, Medical University Vienna, Vienna, Austria; ⁴Department of Clinical Pathology, Medical University Vienna, Vienna, Austria; ⁵True North Therapeutics Inc., San Frnacisco; ⁶Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Canada
Study purpose:The classical pathway (CP) of complement may significantly contribute to antibody-mediated rejection (ABMR). Blockade of CP key component C1 may be a promising strategy…
2017 American Transplant Congress
Donor Warm Ischemic Time >80min Is an Important Predictor of Kidney Graft Survival from Donors After Cardiac Death.
J. Chen,¹ D. Mikhail,² H. Sharma,³ A. Hijazi,¹ D. Nap,¹ L. Stitt,⁴ J. Jevnikar,⁵ M. Cooper,⁶ P. Luke,² A. Sener.²
¹Schulich School of Medicine & Dentistry, London, Canada; ²Urology, Western University, London, Canada; ³General Surgery, Western University, London, Canada; ⁴LW Stitt Statistical Services, London, Canada; ⁵Engineering, Ryerson University, Toronto, Canada; ⁶Georgetown University, Washington
We analyzed UNOS data to determine how donor warm ischemic time (WIT), donor BMI, donor hypertension (dHTN), cold ischemic time (CIT), and vasopressin use in…
2017 American Transplant Congress
Simple Kidney Transplant Graft Survival (KTGS) Calculator Predicts 5- and 10-Year Allograft Survival.
P. Sood,¹ W. Cherikh,² R. Mehta,¹ A. Tevar,¹ S. Hariharan.¹
¹Transplant, University of Pittsburgh, Pittsburgh; ²Research Department, United Network for Organ Sharing, Richmond
To develop a predictive 5- and 10-year Kidney Transplant Graft Survival (KTGS) calculator at the time of transplant for living donor (LD) and deceased (DD)…
2017 American Transplant Congress
Similar Elevation of Gene Expression Associated with Antibody-Mediated Rejection (ABMR) of Renal Allografts Can Be Detected in Both Plasma Exosomes (pExo) and Biopsies (Bx) by Assessing mRNA Transcript Profiles.
H. Zhang,¹ C. Nast,² J. Doldron,² M. Cheung,² J. Mirocha,³ J. Kahwaji,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles; ²Pathology, Cedars-Sinai Medical Center, Los Angeles; ³Biostatistics Center, Cedars-Sinai Medical Center, Los Angeles
Background: ABMR is a major obstacle for successful transplant in HLA-sensitized patients (Pts). Prediction of ABMR by non-invasive diagnostic tools is desirable. Previously we showed…
2017 American Transplant Congress
Transplant Readiness Assessment Clinic: A New Approach to Kidney Waitlist Management in the KAS Era.
X. Cheng,¹ J. Lee,² Z. Tulu,² J. Tan.²
¹Div Nephrology, Stanford University, Palo Alto; ²Kidney Transplant Program, Stanford University, Palo Alto, CA
Kidney waitlist management has become increasingly complex in regions with long wait times. Increasing transplant options and the new Kidney Allocation System has added to…
2017 American Transplant Congress
How to Improve Pre-Kidney Transplant Education for Hispanics: Preferences and Perceptions of Northwestern Memorial Hospital's Hispanic Transplant Program.
H. Gomez, E. Malagon-Blackwell, J. Caicedo.
The Comprehensive Transplantation Center, Northwestern University Feinberg School of Medicine, Chicago, IL
Context: Pre-Transplant educational sessions improve access to transplantation. Currently, however, there is lack of culturally competent approaches to improve living kidney donation for Hispanics Americans.…
2017 American Transplant Congress
Belatacept Conversion for Calcineurin Inhibitor (CNI) Toxicity: Our First 100 Patients.
R. Crew, S. Patel, A. Pai, I. Batal, H. Fernandez.
Columbia University, New York
Intro: CNIs improve kidney transplant (KT) survival, but have significant toxicities, including graft dysfunction (GD), neurotoxicity (NT), or thrombotic microangiopathy (TMA). Belatacept is an alternative…